Iparomlimab and Tuvonralimab

DRUG14 trials

Sponsors

Shandong Cancer Hospital and Institute, Peking Union Medical College Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Sun Yat-sen University, Jinan Central Hospital

Conditions

BRAF V600 Colorectal CancerCervical CancerFirst-line Treatment Failure Nasopharyngeal CarcinomaGastric / Gastroesophageal Junction AdenocarcinomaGastric Cancer (GC)Gastric Cancer Adenocarcinoma MetastaticHCC - Hepatocellular CarcinomaHR-positive/HER2-negative Breast Cancer

Phase 2

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

RecruitingNCT06942416

Shandong Cancer Hospital and InstituteCervical Cancer, Neoplasm Recurrence, Local, Oligometastatic

Start: 2025-02-28End: 2028-12-31Target: 36Updated: 2025-04-24

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

RecruitingNCT07014150

Peking Union Medical College HospitalHepatocellular Carcinoma Resectable

Start: 2025-06-10End: 2027-05-31Target: 33Updated: 2026-05-05

Iparomlimab and Tuvonralimab in HNSCC

RecruitingNCT07090317

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2025-07-31End: 2028-08-01Target: 30Updated: 2025-07-31

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

RecruitingNCT07101744

Sun Yat-sen UniversityFirst-line Treatment Failure Nasopharyngeal Carcinoma, Nasopharyngeal Carcinoma (NPC)

Start: 2025-10-17End: 2030-07-16Target: 41Updated: 2026-01-23

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Not yet recruitingNCT07116577

Jinan Central HospitalmCRC

Start: 2025-08-31End: 2028-12-31Target: 37Updated: 2025-08-11

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

Not yet recruitingNCT07127822

Peking UniversityGastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer

Start: 2025-09-01End: 2028-12-31Target: 106Updated: 2025-08-17

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

RecruitingNCT07150247

Sun Yat-sen UniversityBRAF V600 Colorectal Cancer

Start: 2025-06-01End: 2028-06-30Target: 20Updated: 2025-09-26

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

RecruitingNCT07165847

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityGastric Cancer (GC), Immunotherapy, Neoadjuvant Chemoimmunotherapy +2

Start: 2025-07-23End: 2030-12-31Target: 40Updated: 2025-09-10

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

Not yet recruitingNCT07383285

Peking University Cancer Hospital & InstituteRectal Neoplasms Malignant

Start: 2026-02-01End: 2029-12-31Target: 106Updated: 2026-02-03

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

RecruitingNCT07392346

Dai, GuanghaiGastric Cancer Adenocarcinoma Metastatic

Start: 2025-12-01End: 2028-11-30Target: 68Updated: 2026-02-11

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

RecruitingNCT07396324

RenJi HospitalHR-positive/HER2-negative Breast Cancer

Start: 2026-05-01End: 2031-12-01Target: 55Updated: 2026-05-13

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Not yet recruitingNCT07446387

Jiangsu Cancer Institute & HospitalMetastatic Colorectal Cancer (CRC)

Start: 2026-05-30End: 2029-12-31Target: 70Updated: 2026-05-12

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Not yet recruitingNCT07515469

Tianjin Medical University Cancer Institute and HospitalHCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant Immunotherapy

Start: 2026-05-30End: 2030-10-30Target: 30Updated: 2026-04-07

Unknown Phase

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

RecruitingNCT07546383

The Second Affiliated Hospital of Hainan Medical UniversitySquamous Cell Carcinoma of Head and Neck

Start: 2026-04-13End: 2028-12-31Target: 32Updated: 2026-04-22